Business
Sweden's Flerie acquires Biosergen to revive clinical-stage antifungal candidate
Sweden-based Flerie AB (Nasdaq Stockholm: FLERIE) has agreed to acquire Sweden-based Biosergen AB through a statutory merger, valuing Biosergen at...
Ipsen buys Kartos to add Phase III MDM2 inhibitor for myelofibrosis
France-based Ipsen (Euronext: IPN; ADR: IPSEY) has agreed to acquire Kartos Therapeutics, a Redwood City, California-based clinical-stage company, in a...
Nippon Shinyaku bets on Elixirgen's full-length dystrophin mRNA
Japan-based Nippon Shinyaku Co., Ltd. has signed an option agreement with Baltimore-based Elixirgen Therapeutics, Inc. granting it the right to acquire...
Idorsia secures USD 278m debt facility to extend runway as insomnia franchise scales
Switzerland-based Idorsia Pharmaceuticals Ltd (SWX: IDIA) confirmed the closing of a senior secured term loan facility of up to CHF 250 million...
Ligand raises USD 700m to fund USD 739m XOMA royalty acquisition
Jupiter, Florida-based Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announced the closing of a USD 700 million offering of 0.00% convertible senior...
Nuvation Bio raises USD 250m in convertible notes
New York-based Nuvation Bio, Inc. (NYSE: NUVB) announced the pricing of an upsized convertible senior notes offering totaling USD 250 million, with proceeds...
Optimeos secures backing for non-viral nano gene therapy delivery
Princeton, New Jersey-based Optimeos Life Sciences has announced an investment from Hatch BioFund, an early-stage life sciences venture capital firm...
Lycia raises USD 75m to advance novel extracellular protein degradation into early clinical trials
South San Francisco-based Lycia Therapeutics, Inc., a clinical-stage biotechnology company developing therapeutics designed to degrade disease-causing...
Remix Therapeutics takes Nasdaq listing through Passage Bio reverse merger, USD 100m raise
Philadelphia-based Passage Bio (Nasdaq: PASG) and Watertown, Massachusetts-based Remix Therapeutics have announced a definitive all-stock merger agreement...
Eli Lilly doubles down on ProQR with USD 59.2m funding round
Netherlands-based ProQR Therapeutics N.V. (Nasdaq: PRQR) announced the pricing of a combined underwritten registered direct offering and concurrent private...
Taysha raises USD 200m to advance Rett syndrome gene therapy independently after Astellas exit
Dallas-based Taysha Gene Therapies (Nasdaq: TSHA) announced the pricing of an underwritten public offering of common stock and pre-funded warrants, raising...
Oblenio raises USD 62m to test tri-specific T-cell engager in autoimmune disease
Cambridge, Massachusetts-based Oblenio Bio, Inc. has closed an oversubscribed USD 62 million Series B financing round to advance LBL-051, its CD19/BCMA/CD3...
CStone completes global rollout of PD-L1 sugemalimab with Australia-New Zealand deal
CStone Pharmaceuticals (HKEX: 2616) has completed its geographic rollout of sugemalimab by signing an exclusive commercialization agreement with Arrotex...
Merck KGaA to aquire life sciences tool firm Bio-Techne for USD 11.3b
Germany-based Merck KGaA agreed to acquire Minneapolis-based Bio-Techne Corporation (Nasdaq: TECH) in an all-cash transaction valued at USD 11.3 billion...
Novartis bets USD 1.9b on Antares' covalent chemistry platform for undruggable cancer targets
Novartis has committed up to USD 1.905 billion to access Boston-based Antares Therapeutics' covalent small molecule discovery engine, in one of the largest...
The AllSci Brief
Systematic R&D and deal news. Daily.